BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 28236856)

  • 21. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation.
    Godder KT; Henslee-Downey PJ; Mehta J; Park BS; Chiang KY; Abhyankar S; Lamb LS
    Bone Marrow Transplant; 2007 Jun; 39(12):751-7. PubMed ID: 17450185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
    Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Graft monocytic myeloid-derived suppressor cell content predicts the risk of acute graft-versus-host disease after allogeneic transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood stem cells.
    Vendramin A; Gimondi S; Bermema A; Longoni P; Rizzitano S; Corradini P; Carniti C
    Biol Blood Marrow Transplant; 2014 Dec; 20(12):2049-55. PubMed ID: 25246295
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation.
    Baron F; Labopin M; Niederwieser D; Vigouroux S; Cornelissen JJ; Malm C; Vindelov LL; Blaise D; Janssen JJ; Petersen E; Socié G; Nagler A; Rocha V; Mohty M
    Leukemia; 2012 Dec; 26(12):2462-8. PubMed ID: 22699419
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of acute and chronic graft-versus-host disease on normal and malignant B-lymphoid precursors after allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukemia.
    Sánchez-García J; Serrano J; Gómez P; Martínez F; Martín C; Román-Gómez J; Rodríguez A; Herrera C; García JM; Alvarez MA; Torres A
    Haematologica; 2006 Mar; 91(3):340-7. PubMed ID: 16531257
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group.
    Jacobsen N; Badsberg JH; Lönnqvist B; Ringdén O; Volin L; Rajantie J; Nikoskelainen J; Keiding N
    Bone Marrow Transplant; 1990 Jun; 5(6):413-8. PubMed ID: 2164434
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Who is the best hematopoietic stem-cell donor for a male patient with acute leukemia?
    Ringdén O; Labopin M; Solders M; Beelen D; Arnold R; Ehninger G; Milpied N; Niederwieser D; Hamladji RM; Kyrcz-Krzemien S; Ganser A; Socié G; Stelljes M; Volin L; Craddock C; Mohty M;
    Transplantation; 2014 Sep; 98(5):569-77. PubMed ID: 24798307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TcRαβ-depleted haploidentical transplantation results in adult acute leukemia patients.
    Kaynar L; Demir K; Turak EE; Öztürk ÇP; Zararsız G; Gönen ZB; Gökahmetoğlu S; Şıvgın S; Eser B; Köker Y; Solmaz M; Ünal A; Çetin M
    Hematology; 2017 Apr; 22(3):136-144. PubMed ID: 27724812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
    Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dendritic cell recovery after allogeneic stem-cell transplantation in acute leukemia: correlations with clinical and transplant characteristics.
    Porta MD; Rigolin GM; Alessandrino EP; Maiocchi M; Malcovati L; Vanelli L; Baratè C; Rumi E; Ciccone M; Cuneo A; Lazzarino M; Castoldi G
    Eur J Haematol; 2004 Jan; 72(1):18-25. PubMed ID: 14962258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant.
    de Lima M; van Besien K; Gajewski J; Khouri I; Andersson B; Korbling M; Champlin R; Giralt S
    Bone Marrow Transplant; 2000 Aug; 26(3):333-8. PubMed ID: 10967575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ocular manifestations of graft versus host disease following bone marrow transplantation.
    Claes K; Kestelyn P
    Bull Soc Belge Ophtalmol; 2000; (277):21-6. PubMed ID: 11126670
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of graft-versus-host disease: a biomarker panel based on lymphocytes and cytokines.
    Budde H; Papert S; Maas JH; Reichardt HM; Wulf G; Hasenkamp J; Riggert J; Legler TJ
    Ann Hematol; 2017 Jul; 96(7):1127-1133. PubMed ID: 28447161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time--a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT).
    Frassoni F; Labopin M; Gluckman E; Prentice HG; Vernant JP; Zwaan F; Granena A; Gahrton G; De Witte T; Gratwohl A; Reiffers J; Gorin NC
    Bone Marrow Transplant; 1996 Jan; 17(1):13-8. PubMed ID: 8673048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical effect of reduced-intensity conditioning regimen containing antithymocyte globulin for hematopoietic cell transplantation from unrelated-donors.
    Lee KH; Choi SJ; Lee JH; Lee JH; Kim DY; Seol M; Lee YS; Kang YA; Jeon M; Yun SC; Joo YD; Lee WS; Kang MJ; Kim H; Park JH; Bae SH; Ryoo HM; Kim MK; Hyun MS
    Am J Hematol; 2011 May; 86(5):399-405. PubMed ID: 21523798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Mismatched hematopoietic stem cell transplantation using GIAC protocol: report of 100 cases].
    Han W; Lu DP; Huang XJ; Liu KY; Chen H; Xu LP; Liu DH; Jiang Q; Chen YH; Lu J; Wang JB; Wu T; Dong LJ; Ren HY
    Zhonghua Xue Ye Xue Za Zhi; 2004 Aug; 25(8):453-7. PubMed ID: 15555258
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: antileukemic activity of chronic graft-versus-host disease.
    Lee S; Cho BS; Kim SY; Choi SM; Lee DG; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Shin WS; Kim CC
    Biol Blood Marrow Transplant; 2007 Sep; 13(9):1083-94. PubMed ID: 17697971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Graft-versus-leukemia in rat MHC-mismatched bone marrow transplantation is merely an allogeneic effect.
    Kloosterman TC; Martens AC; van Bekkum DW; Hagenbeek A
    Bone Marrow Transplant; 1995 Apr; 15(4):583-90. PubMed ID: 7655385
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Demodicidosis simulating acute graft-versus-host disease after allogeneic stem cell transplantation in one patient with acute lymphoblastic leukemia.
    Román-Curto C; Meseguer-Yebra C; Cañueto J; Fraile-Alonso C; Santos-Briz A; Vázquez L; Fernández-López E
    Transpl Infect Dis; 2012 Aug; 14(4):387-90. PubMed ID: 22487272
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of multipotent mesenchymal stromal cells used for acute graft-versus-host disease prophylaxis.
    Kuzmina LA; Petinati NA; Shipounova IN; Sats NV; Bigildeev AE; Zezina EA; Popova MD; Drize NJ; Parovichnikova EN; Savchenko VG
    Eur J Haematol; 2016 Apr; 96(4):425-34. PubMed ID: 26115424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.